Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Phase 2
Not yet recruiting
- Conditions
- Recurrent Ovarian Cancer
- Interventions
- Drug: Fuzuloparib Combination with Bevacizumab
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05819060
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cente, Shanghai, Shanghai, China
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
Phase 2
Not yet recruiting
- Conditions
- Hormone Receptor-positive Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 23
- Registration Number
- NCT05806047
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3
Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabineDrug: nab-paclitaxel, with maintenance of capecitabineDrug: VEGFR and TPC
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 192
- Registration Number
- NCT05806060
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05797987
- Locations
- 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China
Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)
Recruiting
- Conditions
- Lung AdenocarcinomaPathologySurgical Procedure, Unspecified
- Interventions
- Procedure: Surgical resection
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1063
- Registration Number
- NCT05794711
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)
Recruiting
- Conditions
- PathologyLung AdenocarcinomaSurgical Procedure, Unspecified
- Interventions
- Procedure: Surgical resection
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1063
- Registration Number
- NCT05794724
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1014)
Recruiting
- Conditions
- Lung AdenocarcinomaSurgical Procedure, UnspecifiedPathology
- Interventions
- Procedure: Surgical resection
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1063
- Registration Number
- NCT05794698
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05781074
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
Phase 2
Recruiting
- Conditions
- Stage II-IIIANeoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05775796
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
Phase 1
Recruiting
- Conditions
- High-Risk Localized Soft Tissue Sarcoma
- Interventions
- Drug: Anti-PD-1 monoclonal antibodyRadiation: Radiotherapy
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05774275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath